• Sorafenib (BAY-43-9006): Mechanism & Research Use

  2026-08-26

  Sorafenib, also known as BAY-43-9006, is an orally bioavailable multikinase inhibitor used to study RAF signaling, VEGF-driven angiogenesis, and tumor proliferation inhibition. Product-reported biochemical and cellular benchmarks support its use as a cancer biology research tool, while an unreviewed preprint provides preliminary evidence for host-directed Ebola virus research.

• PF-562271 HCl in FAK/Pyk2 Cancer Research

  2026-08-25

  Build a mechanism-focused workflow around PF-562271 HCl to test how FAK/Pyk2-dependent adhesion signaling influences melanoma growth, migration, and treatment response. The guide combines phospho-FAK measurements, IFNγ-induced death assays, live imaging, and troubleshooting strategies while clearly separating published findings from practical extensions.

• EDTA-Free Protease Inhibitor Cocktail for Protein Stability

  2026-08-25

  The Protease Inhibitor Cocktail is an EDTA-Free Protease Inhibitor formulation for protecting proteins during cell and tissue extraction. Its multi-class inhibitor design supports protein stability in Western blotting, immunoprecipitation, pull-down, immunofluorescence, immunohistochemistry, and kinase workflows, while its use in OXPHOS studies remains a sample-preparation aid rather than a treatment mechanism.

• Tofacitinib: From JAK Signaling to RA Macrophage Repair

  2026-08-24

  Tofacitinib is best known as a JAK pathway modulator, but emerging rheumatoid arthritis research positions CP-690550 as a tool for studying macrophage state, STAT5 activity, mitochondrial stress, and cytokine-network reprogramming. This article translates those findings into practical assay design, competitive strategy, and translational decision points.

• Resazurin Cell Viability Assay Kit for Translation

  2026-08-23

  A mechanistic and translational framework for using resazurin reduction to connect cell viability signals with apoptosis, oxidative stress, and therapeutic decision-making. Anchored by parthenolide research in lymphoid malignancies, this article explains how the Resazurin Cell Viability Assay Kit can strengthen experimental design, screening workflows, and evidence-based interpretation.

• Veratridine Workflows for Sodium Channel Research

  2026-08-22

  Veratridine is a voltage-gated sodium channel opener that converts channel activation into a controllable assay variable for excitotoxicity, seizure, cardiomyocyte, and blocker-screening workflows. Its persistent depolarization mechanism also complements chamber-specific cardiac models, enabling researchers to ask whether right ventricular-like cells respond differently from conventional cardiomyocytes.

• Resazurin Cell Viability Assay Kit Guide

  2026-08-21

  The Resazurin Cell Viability Assay Kit provides fluorescence- or colorimetric-based measurement of cellular metabolic activity as a practical cell viability assay. Its ready-to-use format, broad sample compatibility, and reported fluorescence sensitivity support screening and mechanistic studies when redox-related limitations are controlled.

• Caffeic Acid Phenethyl Ester (CAPE) Workflows

  2026-08-21

  Caffeic Acid Phenethyl Ester (CAPE) is a focused chemical probe for separating NF-κB-dependent inflammation from broader cellular stress. This guide connects CAPE NF-κB assays with Fyn-driven neuroinflammation, angiogenesis, VEGF modulation, and tumor-invasion workflows while emphasizing solvent control and pathway-specific validation.

• Bestatin Hydrochloride: Reading Enzyme Biology

  2026-08-20

  Bestatin hydrochloride (Ubenimex) is more than a generic aminopeptidase inhibitor: its effects depend on substrate processing, cellular context, and assay design. This article translates classic neuronal evidence into a rigorous framework for angiogenesis inhibition, tumor growth and invasion research, and reproducible cancer research workflows.

• VX-702: Selective p38α MAPK Inhibitor Guide

  2026-08-20

  VX-702 is an ATP-competitive p38α MAPK inhibitor with a reported IC50 range of 4–20 nM in the supplier-described assay context. Evidence supports research applications spanning cytokine suppression, collagen-induced arthritis, platelet storage biology, and myocardial ischemia-reperfusion injury, while the cited dephosphorylation study provides mechanistic context rather than direct proof of a VX-702 dual-action effect.

• TPA as a Context-Controlled Signaling Probe

  2026-08-19

  12-O-tetradecanoyl phorbol-13-acetate (TPA) is more than an ERK activator: it is a controllable probe for dissecting stimulus intensity, timing, and pathway cross-talk. This article connects PKC–ERK assay design with force-dependent redox biology while defining the boundaries of the evidence.

• NLRP10, Keratinocyte Survival, and Skin Barrier Function

  2026-08-19

  The reference study identifies NLRP10 as an epidermal homeostasis regulator that supports keratinocyte survival, P63-dependent differentiation, and barrier integrity. Using human atopic dermatitis samples and an air-lift human skin equivalent model, the authors connect reduced NLRP10 activity with caspase-8-mediated cell death and impaired epidermal maturation, suggesting a mechanistic route toward barrier-restoring therapies.

• Cefepime (BMY-28142) Research Workflows

  2026-08-18

  Build more informative bacterial infection models with Cefepime (BMY-28142), from baseline susceptibility testing to dynamic resistance and blood-brain barrier experiments. This guide emphasizes fresh-solution handling, time-resolved pharmacodynamics, CNS-focused controls, and practical troubleshooting for reproducible research.

• Selonsertib (GS-4997): Reframing ASK1 in Kidney Injury

  2026-08-18

  A translational perspective on how Selonsertib (GS-4997) converts ASK1 biology into an experimentally testable strategy for renal inflammation and fibrosis, with practical guidance for lupus nephritis, diabetic kidney disease, and oxidative stress models.

• Nintedanib (BIBF 1120) in ATRX-Deficient Glioma

  2026-08-17

  Nintedanib (BIBF 1120) enables a practical test of VEGFR, FGFR, and PDGFR blockade in ATRX-stratified glioma models. This workflow combines genotype-aware drug screening, apoptosis measurement, and temozolomide combination testing to distinguish pathway dependence from nonspecific toxicity.

454 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page